Last reviewed · How we verify
Sequence 5
At a glance
| Generic name | Sequence 5 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- The Effects of 5G Radiation on Skin (NA)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Effectiveness of Mindful Attention Awareness Breathing on Attention and Wellbeing Among Undergraduate Students (NA)
- Feasibility Study of a Novel Automated Slit Lamp Camera (Lightfield Medical Ophthalmic Camera Model Vscan001) (NA)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
- Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequence 5 CI brief — competitive landscape report
- Sequence 5 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI